Pfizer Tests Lyme Disease Vaccine on Kids, But Experts Question Need
Pfizer on Tuesday said results of Phase 2 clinical trials of its experimental Lyme disease vaccine delivered “positive” results, including among pediatric trial participants. The vaccine “offers Pfizer the chance to add a growth driver to its mammoth vaccine unit,” but some experts say treatment is a better solution.
Pfizer on Tuesday said results of Phase 2 clinical trials of its experimental Lyme disease vaccine delivered “positive” results, including among pediatric trial participants.
The drugmaker is developing the VLA15 vaccine in conjunction with the French biotech firm Valneva, which Pfizer described as “a specialty vaccine company focused on prevention of diseases with major unmet needs.”
VLA15 is a “multivalent protein subunit vaccine,” targeting “the outer surface protein A (OspA) of Borrelia,” the bacteria which causes Lyme disease, Pfizer reported.
The Phase 2 study included adult subjects and children 5 to 17 years old. Overall, 600 healthy participants were enrolled in the study.
“VLA15 has demonstrated strong immunogenicity and safety data in pre-clinical and clinical studies,” Pfizer said.
According to the two companies, the “positive” results arising from Phase 2, including “positive pediatric data,” will allow them to proceed with a planned Phase 3 trial.
In Phase 2, the companies tested the experimental VLA15 vaccine at two different administration schedules: a two-dose regimen six months apart, and a three-dose regimen with follow-up shots administered at two and six months after the initial administration.
Both schedules involved 180 μg doses.
“VLA15 was found to be more immunogenic than in adults with both vaccination schedules tested,” and “the safety and tolerability profile seen in the 5- to 17-year age group was similar to the previously reported profile in adults,” the companies said.
Similar to claims Pfizer made about booster doses of the COVID-19 vaccines, the drugmaker also said that while the two-dose regimen of VLA15 demonstrated immunity, a third VLA15 dose “increased the level of antibodies against an outer surface protein.”
The companies reported no vaccine-related serious adverse events during the phase 2 trial.
As previously reported by The Defender, in documents submitted to the U.S. Food and Drug Administration (FDA), Pfizer glossed over the adverse effects from its COVID-19 vaccine, while admitting in those same documents that the company hired more than 600 new employees to process reports of vaccine injuries.
The VLA15 trials appear to be the continuation of a trend where pharmaceutical companies envision vaccines as “cure-alls” for everything from the common cold to HIV to cancer.
However, while many of the new vaccines under development utilize messenger RNA (mRNA) technology, this is not the case with VLA15.
‘Growth opportunity’ for Pfizer
Valneva sold the rights to VLA15 to Pfizer for an upfront cost of $130 million in 2020, at which time the two companies announced a collaboration for the continued development and commercialization of the vaccine.
Under the terms of the two companies’ agreement, the first dose in the Phase 2 study triggered an additional $10 million payment from Pfizer to Valneva.
According to Fierce Biotech, a successful Phase 3 trial “could give Pfizer a clear run at a growing opportunity” and “offers Pfizer the chance to add a growth driver to its mammoth vaccine unit,” as the number of reported Lyme disease cases in the U.S. has increased threefold since the late 1990s.
This increase may be due to changes in land use that have brought more humans into proximity with the ticks that transmit Borrelia.
Citing data from the Centers for Disease Control and Prevention (CDC), Pfizer said approximately 476,000 Americans are diagnosed and treated for Lyme disease each year, plus an additional 200,000 cases reported annually in Europe.
Lyme disease is considered the most prevalent vector-borne illness in the Northern Hemisphere.
The increase in Lyme infections led the CDC to declare, “new tools for preventing tick-borne diseases are needed urgently.”
In the 1990s, SmithKline Beecham secured approval for a Lyme vaccine, which was later pulled from the market.
During that same period, Pasteur Mérieux Connaught — now known as Sanofi — also sought approval for a Lyme disease vaccine, before abandoning the effort.
Experts question need
While the CDC has called for “new tools” to prevent the spread of tick-borne diseases, some medical analysts questioned the specific need for a vaccine.
According to Brian Hooker, Ph.D., chief scientific officer for Children’s Health Defense, effective treatments already exist for Lyme disease.
Hooker told The Defender:
“Lyme disease, which is caused by the bacteria Borrelia burgdorferi via tick bite from the black-legged tick, is treatable by standard antibiotics.
“Rather than introducing another aluminum-adjuvanted vaccine for children and adolescents, it seems more prudent to focus on early diagnosis and treatment of the disease.”
Mark Crispin Miller, a professor of media studies at New York University who has experienced the symptoms of Lyme disease, drew comparisons between the experimental Lyme disease vaccine and the COVID-19 vaccines.
Miller told The Defender:
“No doubt the CDC/FDA will bless this Lyme vaccine, regardless of its risks, just as they’ve pushed the COVID ‘vaccines’ for the last two years.
“And their support for this new vaccine is especially perverse, since the CDC et al. have long denied that ‘chronic Lyme’ exists, because its proper treatment would cost more than the insurance carriers want to pay.”
Despite his own difficulties with Lyme, Miller said he sees no reason to pursue a Lyme vaccine:
“As one who has been battling Lyme for more than 10 years, and at enormous cost, I see no reason to put any trust at all in those authorities, whose long denial of the reality of this condition has done me, and countless others, grievous harm.”